Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.
Co-Diagnostics (Nasdaq: CODX) announced its participation at the 17th Annual Next Generation Dx Summit from August 18-20, 2025, at the Capital Hilton in Washington, D.C. The company will showcase its Logix Smart庐 clinical laboratory solutions at Booth #12 and provide information about its upcoming Co-Dx PCR diagnostics platform.
The summit serves as a platform for international thought leaders in diagnostic advancement and technology innovation. Visitors can learn about CODX's pipeline of upper respiratory, tuberculosis and HPV tests planned for clinical evaluations in 2025. The company's attendance is partially funded by a World Trade Center Utah grant.
Co-Diagnostics (Nasdaq: CODX) parteciper脿 al 17掳 Next Generation Dx Summit, in programma dal 18 al 20 agosto 2025 presso il Capital Hilton di Washington, D.C. L'azienda presenter脿 le proprie soluzioni di laboratorio clinico Logix Smart庐 allo stand n. 12 e fornir脿 dettagli sulla prossima piattaforma diagnostica Co-Dx PCR.
Il summit riunisce leader internazionali nell'innovazione diagnostica e tecnologica. I visitatori potranno informarsi sulla pipeline di CODX, che include test per le vie respiratorie superiori, la tubercolosi e l'HPV previsti per valutazioni cliniche nel 2025. La partecipazione dell'azienda 猫 in parte finanziata da una sovvenzione del World Trade Center Utah.
Co-Diagnostics (Nasdaq: CODX) participar谩 en la 17.陋 Cumbre Anual Next Generation Dx del 18 al 20 de agosto de 2025 en el Capital Hilton de Washington, D.C. La compa帽铆a exhibir谩 sus soluciones de laboratorio cl铆nico Logix Smart庐 en el stand n.潞 12 y ofrecer谩 informaci贸n sobre su pr贸xima plataforma diagn贸stica Co-Dx PCR.
La cumbre re煤ne a l铆deres internacionales en avance diagn贸stico e innovaci贸n tecnol贸gica. Los asistentes podr谩n conocer la cartera de CODX, que incluye pruebas para v铆as respiratorias superiores, tuberculosis y VPH previstas para evaluaciones cl铆nicas en 2025. La asistencia de la empresa est谩 parcialmente financiada por una subvenci贸n del World Trade Center Utah.
Co-Diagnostics (Nasdaq: CODX)電� 2025雲� 8鞗� 18鞚茧秬韯� 20鞚缄箤歆� 鞗岇嫳韯� D.C.鞚� 旌愴敿韯� 頌愴劥鞐愳劀 鞐措Μ電� 鞝�17須� Next Generation Dx 靹滊皨鞐� 彀戈皜頃╇媹雼�. 須岇偓電� 鞛勳儊 瓴�靷� 靻旊（靺� Logix Smart庐鞚� 攵�鞀� #12鞐愳劀 靹犽炒鞚措┌ 彀赴 歆勲嫧 頂岆灚韽检澑 Co-Dx PCR鞐� 雽�頃� 鞝曤炒毳� 鞝滉车頃╇媹雼�.
鞚措矆 靹滊皨鞚� 歆勲嫧 旮办垹 氚滌爠瓿� 順侅嫚鞚� 雲检潣頃橂姅 甑牅鞝� 毽崝霌れ潣 鞛レ瀰雼堧嫟. 氚╇臧濍摛鞚� CODX臧� 2025雲勳棎 鞛勳儊 韽夑皜毳� 瓿勴殟 欷戩澑 靸侁赴霃�(順疙潯旮�), 瓴绊暤 氚� HPV 瓴�靷� 韺岇澊頂勲澕鞚胳棎 雽�頃� 鞎岇晞氤� 靾� 鞛堨姷雼堧嫟. 須岇偓鞚� 彀胳劃鞚� World Trade Center Utah鞚� 氤挫“旮堨溂搿� 鞚茧秬 歆�鞗愲惄雼堧嫟.
Co-Diagnostics (Nasdaq: CODX) participera au 17e sommet annuel Next Generation Dx qui se tiendra du 18 au 20 ao没t 2025 au Capital Hilton de Washington, D.C. La soci茅t茅 pr茅sentera ses solutions de laboratoire clinique Logix Smart庐 au stand n掳12 et fournira des informations sur sa future plateforme diagnostique Co-Dx PCR.
Le sommet r茅unit des experts internationaux en progr猫s diagnostique et innovation technologique. Les visiteurs pourront d茅couvrir le pipeline de CODX, comprenant des tests pour les voies respiratoires sup茅rieures, la tuberculose et le HPV, pr茅vus pour des 茅valuations cliniques en 2025. La participation de la soci茅t茅 est partiellement financ茅e par une subvention du World Trade Center Utah.
Co-Diagnostics (Nasdaq: CODX) nimmt an der 17. j盲hrlichen Next Generation Dx Summit teil, die vom 18. bis 20. August 2025 im Capital Hilton in Washington, D.C. stattfindet. Das Unternehmen stellt seine klinischen Laborl枚sungen Logix Smart庐 an Stand Nr. 12 vor und informiert 眉ber die kommende diagnostische Plattform Co-Dx PCR.
Der Gipfel bringt internationale Meinungsf眉hrer im Bereich Diagnostik und Technologieinnovation zusammen. Besucher k枚nnen sich 眉ber CODX' Pipeline informieren, darunter Tests f眉r obere Atemwege, Tuberkulose und HPV, die 2025 klinisch evaluiert werden sollen. Die Teilnahme des Unternehmens wird teilweise durch einen Zuschuss des World Trade Center Utah finanziert.
- None.
- None.
Cambridge Healthtech Institute's Next Generation Dx Summit is described as the nexus for international thought leaders to network and discuss diagnostic advancement and technology innovation, and offers a valuable window into how point-of-care, decentralized testing, infectious disease, liquid biopsy and companion diagnostics are improving the standard of care in the diagnostics industry.
Attendees are invited to visit the Company at Booth #12 to learn more about the Co-Dx Logix Smart庐 suite of clinical laboratory solutions, as well as the upcoming Co-Dx PCR diagnostics platform* and the pipeline of upper respiratory, tuberculosis and HPV tests, all of which the Company is anticipating entering into clinical evaluations during 2025.
To learn more about the summit, including in-person and virtual registration details, please visit .
Company travel and conference attendance is made possible due in part to a grant from , a member of the World Trade Centers Association founded in 2006 with the goal of helping
*The Co-Dx PCR platform (including the Co-Dx PCR Home鈩�, Co-Dx PCR Pro鈩�, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
听
View original content to download multimedia:
SOURCE Co-Diagnostics
FAQ
When and where is Co-Diagnostics (CODX) presenting at the Next Generation Dx Summit 2025?
What products will Co-Diagnostics (CODX) showcase at the Next Generation Dx Summit?
What new diagnostic tests is Co-Diagnostics (CODX) planning for clinical evaluations?
Is the Co-Dx PCR platform currently available for sale?
